PATH has named Dr. David Shoultz, currently the leader of its drug development program, to expand his leadership role to include PATH's devices and tools program. Based in PATH's Seattle headquarters, he will assume this new role on October 1, 2015.
PATH's devices and tools program drives the development of innovative technology solutions, including the recently launched MSR® SE200™ Community Chlorine Maker and Caya® diaphragm. Shoultz will oversee multidisciplinary teams whose comprehensive capabilities and specialized experience in product design, public health, and building public- and private-sector partnerships accelerate access to appropriate, affordable technologies for low-resource communities around the world.
"PATH has been a leader for nearly 40 years in developing fit-for-purpose devices and tools for low-resource settings, from lifesaving maternal, reproductive, child, and newborn technologies to innovative vaccine and pharmaceutical technologies," said Dr. David C. Kaslow, vice president for product development at PATH. "Dr. Shoultz's leadership, strategy and operations, and business development experience, combined with his strong passion for global health equity, have well-positioned him to guide this program toward continued impactful, inventive work."
Prior to his work at PATH, Shoultz served as the director of grantee and partner engagement at the Bill & Melinda Gates Foundation and as a member of the Gates Foundation's leadership team. In this position, he led an effort to strengthen the relationships with its partner organizations to facilitate ongoing interactions and help achieve maximum impact. Shoultz also served as a deputy director in the Gates Foundation's Global Health Program, Infectious Disease, where he was central to strategy, planning, and management for four strategic program teams, including malaria, enteric diseases, pneumonia, and neglected tropical diseases.
Prior to his roles at the Gates Foundation, Shoultz worked as a member of the senior management team for a number of clinical research organizations participating in the development of new medicines, including PPD Development, PRA International, and Biomedical Systems. His significant experience in working with partners and creating and leading successful strategic business plans is mirrored by his deep commitment for integrated product and market development for global health impact.
Shoultz earned his PhD and MS from the University of Washington School of Public Health, where he also obtained his BSN. He holds an MBA from the Albers School of Business and Economics at Seattle University, where he is also a faculty member in the Executive MBA Program. For the past 14 years, he has been a member of the affiliate faculty for the departments of Global Health and Epidemiology at the University of Washington.
Shoultz is a board member and serves as the inaugural chair of the Scientific Advisory Committee for the Geneva Foundation, a nonprofit organization that supports and advances innovative medical research and excellence in education within the U.S. military.